For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Viridian Therapeutics Inc (NASDAQ: VRDN) closed at $15.14 down -5.61% from its previous closing price of $16.04. In other words, the price has decreased by -$5.61 from its previous closing price. On the day, 0.56 million shares were traded. VRDN stock price reached its highest trading level at $15.84 during the session, while it also had its lowest trading level at $15.07.
Ratios:
For a deeper understanding of Viridian Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.43 and its Current Ratio is at 15.43. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on December 19, 2024, Downgraded its rating to Equal Weight and sets its target price to $27 from $37 previously.
Needham reiterated its Buy rating for the stock on September 11, 2024, while the target price for the stock was revised from $30 to $38.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 27 ’24 when Beetham Thomas W. bought 5,000 shares for $23.41 per share. The transaction valued at 117,050 led to the insider holds 6,000 shares of the business.
Mahoney Stephen F. bought 21,400 shares of VRDN for $499,262 on Sep 27 ’24. The President and CEO now owns 21,400 shares after completing the transaction at $23.33 per share. On Sep 13 ’24, another insider, Fairmount Funds Management LLC, who serves as the Director of the company, bought 1,600,000 shares for $18.75 each. As a result, the insider paid 30,000,000 and bolstered with 3,445,813 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRDN now has a Market Capitalization of 1233682944 and an Enterprise Value of 728102144. For the stock, the TTM Price-to-Sale (P/S) ratio is 4112.27 while its Price-to-Book (P/B) ratio in mrq is 2.54. Its current Enterprise Value per Revenue stands at 2410.934 whereas that against EBITDA is -2.439.
Stock Price History:
The Beta on a monthly basis for VRDN is 0.78, which has changed by -0.1635359 over the last 52 weeks, in comparison to a change of 0.07465422 over the same period for the S&P500. Over the past 52 weeks, VRDN has reached a high of $27.20, while it has fallen to a 52-week low of $11.40. The 50-Day Moving Average of the stock is -12.91%, while the 200-Day Moving Average is calculated to be -15.62%.
Shares Statistics:
For the past three months, VRDN has traded an average of 1.13M shares per day and 688080 over the past ten days. A total of 80.99M shares are outstanding, with a floating share count of 73.28M. Insiders hold about 10.07% of the company’s shares, while institutions hold 102.34% stake in the company. Shares short for VRDN as of 1740700800 were 9567139 with a Short Ratio of 8.50, compared to 1738281600 on 10881666. Therefore, it implies a Short% of Shares Outstanding of 9567139 and a Short% of Float of 13.29.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
